Skip Nav Destination

In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment.

J Exp Med (1990) 171 (3): 645–658.
Currently there are no citedby results. Try again later.